Triple receptor negative breast cancer (TNBC) is a molecular subtype characterized by the lack of estrogen receptor (ER), progesterone receptor (PR), and receptor for human epidermal growth factor-2 (HER2), making it unsuitable for endocrine or targeted antibody therapy [1]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.